Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Obama follow Clinton on biogenerics?

Executive Summary

After adding "presumptive nominee" to his resumé, Sen. Barack Obama may be poised to add more planks to his health care platform as well. While the Illinois Democrat supports the concept of follow-on biologics, he has not signed on to legislation that would create a pathway for approval - in part, perhaps, to avoid assisting his main rival Sen. Hillary Clinton, D-N.Y., who is one of the lead sponsors. But with the primary campaign over, there is some indication that follow-ons may now enter Obama's messaging, which would presumably also lead him to flesh out his policy position on the issue. On June 4, the Alliance of Minority Medical Associations and the Benenson Strategy Group - which bills itself as the "polling firm for Barack Obama's campaign" - released survey data showing "overwhelming" public support for follow-on biologics. Regardless of what rhetorical positioning is adopted on the campaign trail, however, it seems unlikely there will be any legislative movement on follow-on biologics this year

You may also be interested in...



Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

Novartis Holds Out For Happier Second Half Of 2020

The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel